These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 25289928)

  • 21. Osteocytes produce interferon-β as a negative regulator of osteoclastogenesis.
    Hayashida C; Ito J; Nakayachi M; Okayasu M; Ohyama Y; Hakeda Y; Sato T
    J Biol Chem; 2014 Apr; 289(16):11545-11555. PubMed ID: 24610813
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of TNF-
    Ohori F; Kitaura H; Marahleh A; Kishikawa A; Ogawa S; Qi J; Shen WR; Noguchi T; Nara Y; Mizoguchi I
    J Immunol Res; 2019; 2019():9716758. PubMed ID: 31341915
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fluid Shear Stress Increases Osteocyte and Inhibits Osteoclasts via Downregulating Receptor-Activator of Nuclear Factor κB (RANK)/Osteoprotegerin Expression in Myeloma Microenvironment.
    Wang X; He Y; Tian S; Zhu F; Huang B; Zhang J; Chen Z; Wang H
    Med Sci Monit; 2019 Aug; 25():5961-5968. PubMed ID: 31400110
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of osteocytes in targeted bone remodeling: a mathematical model.
    Graham JM; Ayati BP; Holstein SA; Martin JA
    PLoS One; 2013; 8(5):e63884. PubMed ID: 23717504
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma.
    McDonald MM; Reagan MR; Youlten SE; Mohanty ST; Seckinger A; Terry RL; Pettitt JA; Simic MK; Cheng TL; Morse A; Le LMT; Abi-Hanna D; Kramer I; Falank C; Fairfield H; Ghobrial IM; Baldock PA; Little DG; Kneissel M; Vanderkerken K; Bassett JHD; Williams GR; Oyajobi BO; Hose D; Phan TG; Croucher PI
    Blood; 2017 Jun; 129(26):3452-3464. PubMed ID: 28515094
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging treatment approaches for myeloma-related bone disease.
    Gavriatopoulou M; Dimopoulos MA; Kastritis E; Terpos E
    Expert Rev Hematol; 2017 Mar; 10(3):217-228. PubMed ID: 28092987
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pathogenesis and management of myeloma bone disease.
    Christoulas D; Terpos E; Dimopoulos MA
    Expert Rev Hematol; 2009 Aug; 2(4):385-98. PubMed ID: 21082944
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence for osteocyte regulation of bone homeostasis through RANKL expression.
    Nakashima T; Hayashi M; Fukunaga T; Kurata K; Oh-Hora M; Feng JQ; Bonewald LF; Kodama T; Wutz A; Wagner EF; Penninger JM; Takayanagi H
    Nat Med; 2011 Sep; 17(10):1231-4. PubMed ID: 21909105
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulatory mechanisms of RANKL presentation to osteoclast precursors.
    Honma M; Ikebuchi Y; Kariya Y; Suzuki H
    Curr Osteoporos Rep; 2014 Mar; 12(1):115-20. PubMed ID: 24477414
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The osteocyte and its osteoclastogenic potential.
    Marahleh A; Kitaura H; Ohori F; Noguchi T; Mizoguchi I
    Front Endocrinol (Lausanne); 2023; 14():1121727. PubMed ID: 37293482
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Osteocyte as a Novel Key Player in Understanding Periodontitis Through its Expression of RANKL and Sclerostin: a Review.
    de Vries TJ; Huesa C
    Curr Osteoporos Rep; 2019 Jun; 17(3):116-121. PubMed ID: 30924022
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IL-6 Enhances Osteocyte-Mediated Osteoclastogenesis by Promoting JAK2 and RANKL Activity In Vitro.
    Wu Q; Zhou X; Huang D; Ji Y; Kang F
    Cell Physiol Biochem; 2017; 41(4):1360-1369. PubMed ID: 28278513
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IL-6 exhibits both
    McGregor NE; Murat M; Elango J; Poulton IJ; Walker EC; Crimeen-Irwin B; Ho PWM; Gooi JH; Martin TJ; Sims NA
    J Biol Chem; 2019 May; 294(19):7850-7863. PubMed ID: 30923130
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Parathyroid hormone (PTH)/PTH-related peptide type 1 receptor (PPR) signaling in osteocytes regulates anabolic and catabolic skeletal responses to PTH.
    Saini V; Marengi DA; Barry KJ; Fulzele KS; Heiden E; Liu X; Dedic C; Maeda A; Lotinun S; Baron R; Pajevic PD
    J Biol Chem; 2013 Jul; 288(28):20122-34. PubMed ID: 23729679
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of osteoclast differentiation and collagen antibody-induced arthritis by CTHRC1.
    Jin YR; Stohn JP; Wang Q; Nagano K; Baron R; Bouxsein ML; Rosen CJ; Adarichev VA; Lindner V
    Bone; 2017 Apr; 97():153-167. PubMed ID: 28115279
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The osteocyte plays multiple roles in bone remodeling and mineral homeostasis.
    Chen H; Senda T; Kubo KY
    Med Mol Morphol; 2015 Jun; 48(2):61-8. PubMed ID: 25791218
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Bone tissue and cancer].
    Rossi JF
    Pathol Biol (Paris); 1990 Jan; 38(1):69-79. PubMed ID: 2407992
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Wnt Inhibitor Sclerostin Is Up-regulated by Mechanical Unloading in Osteocytes in Vitro.
    Spatz JM; Wein MN; Gooi JH; Qu Y; Garr JL; Liu S; Barry KJ; Uda Y; Lai F; Dedic C; Balcells-Camps M; Kronenberg HM; Babij P; Pajevic PD
    J Biol Chem; 2015 Jul; 290(27):16744-58. PubMed ID: 25953900
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resorption controls bone anabolism driven by parathyroid hormone (PTH) receptor signaling in osteocytes.
    Rhee Y; Lee EY; Lezcano V; Ronda AC; Condon KW; Allen MR; Plotkin LI; Bellido T
    J Biol Chem; 2013 Oct; 288(41):29809-20. PubMed ID: 23963454
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pathogenic Mechanisms of Myeloma Bone Disease and Possible Roles for NRF2.
    Yen CH; Hsu CM; Hsiao SY; Hsiao HH
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32937821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.